General Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/22/15Keryx Biopharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11Printer Friendly Version
12/10/15Keryx Announces Appointment of John P. Butler to its Board of DirectorsPrinter Friendly Version
12/01/15Keryx Biopharmaceuticals Announces Webcast of Presentation at Oppenheimer's 26th Annual Healthcare ConferencePrinter Friendly Version
11/03/15Keryx Biopharmaceuticals Announces Participation at Two Upcoming Investor ConferencesPrinter Friendly Version
10/29/15Keryx Biopharmaceuticals Announces Third Quarter 2015 Financial ResultsPrinter Friendly Version
10/21/15Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2015 Financial Results on Thursday, October 29, 2015Printer Friendly Version
10/15/15Keryx Biopharmaceuticals Announces $125 Million Private Placement of Convertible Senior Notes With The Baupost Group, L.L.C.Printer Friendly Version
09/24/15Keryx Receives European Approval for Fexeric(R) (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney DiseasePrinter Friendly Version
09/09/15Keryx Biopharmaceuticals Announces Participation at Upcoming Investor ConferencesPrinter Friendly Version
08/05/15Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial ResultsPrinter Friendly Version
07/28/15Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2015 Financial Results on Wednesday, August 5, 2015Printer Friendly Version
07/27/15Keryx Biopharmaceuticals Appoints Scott A. Holmes as Chief Financial OfficerPrinter Friendly Version
07/24/15Keryx Receives CHMP Positive Opinion for Fexeric(R) (Ferric Citrate Coordination Complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney DiseasePrinter Friendly Version
06/24/15Keryx Announces Two National Insurance Providers Added Auryxia(TM) to Their Medicare Part D FormulariesPrinter Friendly Version
06/16/15Keryx Biopharmaceuticals to Present at the JMP Securities Life Sciences Conference 2015Printer Friendly Version
05/12/15CORRECTING and REPLACING -- Keryx Biopharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care ConferencePrinter Friendly Version
05/05/15Keryx Biopharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care ConferencePrinter Friendly Version
05/04/15Keryx Biopharmaceuticals Announces First Quarter 2015 Financial ResultsPrinter Friendly Version
04/30/15Keryx Biopharmaceuticals Completes Transition of CEO Role to Greg MadisonPrinter Friendly Version
04/27/15Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2015 Financial ResultsPrinter Friendly Version
04/23/15Keryx Biopharmaceuticals Appoints John F. Neylan, MD, as Chief Medical OfficerPrinter Friendly Version
03/10/15Keryx Biopharmaceuticals Announces Appointment of Greg Madison to Its Board of DirectorsPrinter Friendly Version
03/04/15Keryx Biopharmaceuticals Announces Publication of Auryxia(TM) (ferric citrate) Analysis in Journal of the American Society of NephrologyPrinter Friendly Version
02/27/15Keryx Announces Fourth Quarter and Year-End 2014 Financial ResultsPrinter Friendly Version
02/25/15Keryx Biopharmaceuticals Announces Participation at Upcoming Investor ConferencesPrinter Friendly Version
02/18/15Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2014 Financial ResultsPrinter Friendly Version
01/21/15Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common StockPrinter Friendly Version
01/20/15Keryx Biopharmaceuticals, Inc. Announces $100 Million Proposed Public Offering of Common StockPrinter Friendly Version
01/11/15Keryx Biopharmaceuticals Announces Transition of LeadershipPrinter Friendly Version
01/07/15Keryx Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version